Saturday, 31 October 2026European Markets

LISI Stock Bullish Momentum With A 12% Rise So Far On Friday

Loading stream...

(vianews) - shares of lisi (cac 40: fii.pa) rose by a staggering 12.79% to €24.70 at 13:58 est on friday, after two consecutive sessions in a row of losses. cac 40 is falling 0.48% to €7,282.38, following the last session's upward trend. this seems, as yet, a somewhat negative trend trading session today.

about lisi

lisi s.a. provides assembly and component solutions for the aerospace, automotive, and medical industries in france and internationally. it operates through three divisions: lisi aerospace, lisi automotive, and lisi medical. the company provides titanium nuts, lightning strike protection, safety locks, and fuse pins; compressor blade and strut for the leap engine; leap engines composite fan blade leading edge; air intake lipskin for the airbus; power transmission semi-machined gears; stator vanes; and satellite antenna brackets for airplanes and helicopters. it also offers guide pins and electric parking brakes; braking systems and direct engine injections; screws and nuts; belt and seat mechanism products; special parts for motors and safety systems; clips for interior and exterior trim; assembly reduction and optimization solutions; and cable ducts. in addition, the company provides assembly solutions, battery fastening systems, complex power transmission parts, and other automotive standard fasteners; clipped fastening systems for interior and exterior cladding, fasteners for tubes and cables, as well as solutions for weight reduction and optimizing assemblies; and covers components for braking, fluid management, and seat adjustment and interior safety systems. further, it is involved in the designing and modeling, prototypes, pre-series, materials, process validation, and replenishment of inventories; offers shoulders, reconstruction implants solutions for hips, knees, extremities, and instruments; blades, scissors, staplers, and pliers for surgery; and spinal and trauma implants, such as connectors, screws, cages, plates, and prostheses medical devices for treating trauma and osteosynthesis. the company was formerly known as gfi industries and changed its name to lisi s.a. in 2002. the company was founded in 1777 and is headquartered in belfort, france. lisi s.a. operates as a subsidiary of compagnie industrielle de delle s.a.

earnings per share

as for profitability, lisi has a trailing twelve months eps of €-0.7.

volatility

lisi's last week, last month's, and last quarter's current intraday variation average was a negative 0.30%, a positive 0.36%, and a positive 1.54%.

lisi's highest amplitude of average volatility was 0.46% (last week), 1.65% (last month), and 1.54% (last quarter).

more news about lisi (fii.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com